GlaxoSmithKline plc (GSK) Received “Underperform” Rating from BNP Paribas

GlaxoSmithKline plc (GSK) Received “Underperform” Rating from BNP Paribas

GlaxoSmithKline plc (LON:GSK)‘s stock had its “underperform” rating restated by equities researchers at BNP Paribas in a report released on Tuesday, StockTargetPrices.com reports. They presently have a GBX 1,520 ($19.10) price target on the stock. BNP Paribas’ price objective points to a potential downside of 8.41% from the stock’s previous close.

GSK has been the subject of a number of other research reports. JPMorgan Chase & Co. decreased their price target on shares of GlaxoSmithKline plc from GBX 1,800 ($22.62) to GBX 1,600 ($20.11) and set a “neutral” rating for the company in a research report on Wednesday, January 4th. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline plc in a research report on Friday, January 6th. Jefferies Group LLC raised their price target on shares of GlaxoSmithKline plc from GBX 1,780 ($22.37) to GBX 1,800 ($22.62) and gave the stock a “buy” rating in a research report on Friday, February 17th. Beaufort Securities reissued a “buy” rating and set a GBX 1,750 ($21.99) price target on shares of GlaxoSmithKline plc in a research report on Thursday, February 16th. Finally, Goldman Sachs Group Inc raised their price target on shares of GlaxoSmithKline plc from GBX 1,800 ($22.62) to GBX 1,850 ($23.25) and gave the stock a “buy” rating in a research report on Tuesday, January 24th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have given a buy rating to the stock. GlaxoSmithKline plc presently has an average rating of “Hold” and a consensus target price of GBX 1,743.82 ($21.92).

Shares of GlaxoSmithKline plc (LON:GSK) traded down 1.16% during trading on Tuesday, reaching GBX 1659.50. 12,105,244 shares of the company’s stock were exchanged. GlaxoSmithKline plc has a 52 week low of GBX 1,363.00 and a 52 week high of GBX 1,745.56. The company’s 50-day moving average is GBX 1,655.77 and its 200 day moving average is GBX 1,596.31. The stock’s market capitalization is GBX 80.77 billion.

The business also recently announced a dividend, which will be paid on Thursday, April 13th. Shareholders of record on Thursday, February 23rd will be paid a GBX 23 ($0.29) dividend. This represents a yield of 1.47%. This is a boost from GlaxoSmithKline plc’s previous dividend of $19.00. The ex-dividend date is Thursday, February 23rd.

In related news, insider Moncef Slaoui acquired 56 shares of the business’s stock in a transaction that occurred on Tuesday, March 7th. The shares were acquired at an average cost of GBX 2,072 ($26.04) per share, for a total transaction of £1,160.32 ($1,458.24). Also, insider Simon Dingemans sold 3,589 shares of GlaxoSmithKline plc stock in a transaction dated Wednesday, February 22nd. The shares were sold at an average price of GBX 1,640 ($20.61), for a total transaction of £58,859.60 ($73,972.10). Over the last quarter, insiders acquired 471 shares of company stock worth $786,697 and sold 52,038 shares worth $84,442,106.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Related posts

Leave a Comment